Vicarious Surgical (NYSE:RBOT) develops a next-generation robotic surgical system that integrates virtual reality (VR) with minimally invasive instrumentation. Its flagship offering combines ultra-slender, articulated robotic arms with a VR surgeon console, allowing physicians to perform laparoscopic procedures with enhanced precision, dexterity and visual immersion. The platform is designed to reduce patient trauma compared with traditional open or laparoscopic surgery and to expand surgeon access to challenging operative sites.
The company’s technology is intended for use across multiple surgical specialties, including general surgery, gynecology and urology. In addition to the robotic hardware and VR interface, Vicarious Surgical provides comprehensive training programs, service contracts and remote support tools to help hospitals and surgical centers integrate its system into existing clinical workflows. The company has conducted early-stage clinical evaluations under FDA investigational device exemptions and is pursuing full regulatory clearance in the United States, with plans to seek approvals in key international markets upon U.S. authorization.
Founded in 2014 and headquartered in Boston, Massachusetts, Vicarious Surgical was co-founded by Dr. Adam Sachs, who serves as chief executive officer, and Dr. Justin Ryan, who oversees technology development as chief technology officer. The leadership team combines expertise in robotic engineering, software development and minimally invasive surgery, supported by a board that includes experienced healthcare and medical device executives.
After completing preclinical and feasibility studies, the company went public through a merger with a special purpose acquisition company in late 2021 and trades on the New York Stock Exchange under the ticker RBOT. With a focus on expanding clinical evidence and scaling its commercial infrastructure, Vicarious Surgical aims to bring its VR-enhanced robotic platform into broader surgical practice in the years ahead.
